|POZEN To Present at The UBS Life Sciences Conference|
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Sept. 10, 2008--POZEN Inc. (NASDAQ: POZN) announced today that John R. Plachetka, Pharm.D., the company's chairman, president and chief executive officer, will present at the UBS Life Sciences Conference on Tuesday, September 23, 2008 at 9:30 a.m. (ET) at the Grand Hyatt in New York. Dr. Plachetka's presentation will be webcast and archived on POZEN's home page at www.pozen.com.
POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. POZEN's efforts are focused primarily on the development of pharmaceutical products for the treatment of acute and chronic pain and other pain-related conditions. POZEN has development and commercialization alliances with GlaxoSmithKline for Treximet(TM), which was approved by the United States Food and Drug Administration for the acute treatment of migraine attacks in adults, and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for conditions such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing NSAID-associated gastric ulcers. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.
CONTACT: POZEN Inc.